The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Pharmaceutical Technology

MAY 17, 2023

Under the collaboration, WuXi Biologics will be responsible for providing cGMP manufacturing of Gohibic. The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

Scienmag

MAY 26, 2021

In series of samples collected from individuals vaccinated against COVID-19, an ultrasensitive test detected low concentrations of circulating antigen; Following robust production of antibodies, viral protein declined to undetectable levels The carefully orchestrated dance between the immune system and the viral proteins that induce immunity against (..)

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Pharmaceutical Technology

JANUARY 19, 2023

The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials. Nuvaxovid demonstrated a significant antibody response when given as a booster dose after primary vaccination with other authorised Covid-19 doses in the COV-BOOST trial.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pharmaceutical Technology

DECEMBER 6, 2022

In the partnership’s discovery phase, RAVEN, an artificial intelligence (AI) platform of Evaxion will be leveraged for designing a next-generation vaccine candidate that induces cellular as well as humoral/antibody responses. Using ExpreS 2 ion’s ExpreS2 platform, the company will manufacture the antigen constructs obtained from RAVEN.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

pharmaphorum

JUNE 28, 2022

billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don’t respond to current immunotherapies. The biotech has the option to share costs and profits for developing and commercialising the three product candidates in the US.

Antibody 105

Antibody Immune Response Gene Therapy Drugs 105

pharmaphorum

OCTOBER 31, 2022

The Galien Foundation, which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded its Best Biotechnology Product 2022 accolade to Regeneron Pharmaceuticals, Inc.’s s Inmazeb (consisting of the monoclonal antibodies atoltivimab, maftivimab, and odesivimab-ebgn).

Production 52

Production FDA Approval Antibody Gene 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 16, 2020

To help determine the minimum antibody levels needed to maintain a safe “return to normal” 20/20 plans to urge its antibody test consumers to complete and update cloud accessible health questionnaires and will deploy machine learning to calculate individualized antibody thresholds based on age, race, BMI and other clinical factors.

Antibody 52

Antibody Vaccination Vaccine Immune Response 52

pharmaphorum

JUNE 3, 2021

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million. “Creating bispecific ISACs turbo-charged with potent immune stimulants is a novel concept that has tremendous potential for patients,” he added.

Antibody 52

Antibody Immune Response Clinical Trials Clinical Trials 52

XTalks

OCTOBER 12, 2021

The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. is an autoantigen, which means it is an endogenous antigen that triggers an immune response in the body. antibodies in the knockout (KO) rats. With the finding that 14-3-3?

Vaccination 105

Vaccination Vaccine Research Immune Response 105

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. Antibody levels against the A strains were higher than the B subtypes.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

pharmaphorum

NOVEMBER 30, 2020

Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. As AAV is a virus derived from the common cold, the immune system can easily have levels of pre-existing NAbs that will recognise and neutralise AAV, rendering it ineffective.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

pharmaphorum

FEBRUARY 9, 2022

The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response. over the last five years.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

APRIL 15, 2022

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Food and Drug Administration in the coming days with additional submissions to other regulatory agencies worldwide to follow.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

pharmaphorum

APRIL 14, 2022

Epcoritamab is a bispecific antibody which targets CD3 on white blood cells and CD20 on tumour cells, and is designed to encourage an immune response against the cancer. billion product at peak. Analysts at Jefferies have previously said they think epcoritamab could become a $1.5

Licensing 64

Licensing Licensing Immune Response Antibody 64

pharmaphorum

NOVEMBER 30, 2020

The drug is an antibody-drug conjugate where a monoclonal antibody is linked to monomethyl auristatin, a cancer-killing “payload” It is targeted against AXL, a signalling molecule that is overexpressed in several haematologic and solid malignancies.

Development 52

Development Drugs Antibody Immune Response 52

Pharmaceutical Technology

APRIL 24, 2023

Due to their size, cells can absorb them where they release products. With early nanoparticle studies, researchers often found the human body’s innate immune response to drugs and the short-lasting effects of drugs challenging, as they can also reduce a drug’s efficacy.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed.

Protein 52

Protein Vaccination Vaccine Immune Response 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

XTalks

JUNE 15, 2022

Last week, Novavax announced that it received positive feedback from the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the safety and efficacy of its COVID-9 vaccine (NVX-CoV2373). protein that triggers the immune system to generate antibodies against the virus.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Our pipeline, for example, includes a new class of recombinant antibodies. This is just a quick snapshot of our pipeline developments. The science is brilliant.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

NOVEMBER 10, 2020

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease,” said Landry.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

JANUARY 26, 2021

In a statement, Kyriakides said AZ’s responses to enquiries “have not been satisfactory so far”, and another meeting of EU27 member states has been scheduled for Wednesday to discuss the matter further. Moderna takes on new strains.

Vaccination 69

Vaccination Vaccine Antibody Immune Response 69

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. INTERCHANGEABILITY.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

The Pharma Data

DECEMBER 3, 2020

S-Trimer adjuvanted with GSK’s pandemic adjuvant system induced neutralizing antibody titers (seroconversion) in 100% of participants at the selected 9 µg S-Trimer dose in both adult and elderly groups, with geometric mean titers (GMT) greater than 1:1,800.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Delveinsight

AUGUST 26, 2021

Any products from the collaboration will be developed and commercialized by Roche. The study looks at the frequency of solicited systemic and local reactions in the 39 days after dosing, severe events out as far as Day 393, and changes in the levels of neutralizing antibodies at Day 57 and Day 85.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

OCTOBER 6, 2020

These studies suggest BNT162b2 triggers the production of neutralising antibodies and T-cells that target SARS-CoV-2, the coronavirus that causes COVID-19. The CHMP begun its review of the vaccine, known as BNT162b2 based on preliminary results from pre-clinical and early clinical studies.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

pharmaphorum

FEBRUARY 14, 2022

That heavyweight competition could pose a big challenge to Curevo, which says CRV-101 has the potential to have a better safety profile, production yields and “equivalent effectiveness” to Shingrix, which GSK has predicted will become a $6 billion product at peak.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

The Pharma Data

AUGUST 16, 2021

The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels that significantly exceed those seen after the two-dose primary schedule. today announced that they have submitted Phase 1 data to the U.S. today announced that they have submitted Phase 1 data to the U.S.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Efforts are also underway to enable the product to be stable at routine refrigerator temperature (2-8°C). Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. and Australia.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52